ClinicalTrials.gg
Active, not recruitingNCT04047251Updated Sep 2, 2026

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

A Phase 1 interventional study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors and Merkel Cell Carcinoma, sponsored by Fujifilm Pharmaceuticals U.S.A., Inc.. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Fujifilm Pharmaceuticals U.S.A., Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Carcinoma, Merkel Cell with a site in United States — 26 open to participants now, 47 under way, 3 of them phase 3. Carcinoma, Merkel Cell · United States.

Planned enrollment
29th of 105
96 · median 40
Started
2019
with 14 others
Phase 1
36 of 112
6 open now
Primary completion
2026-12
later than 10 of 46 live
Registered
58th of 112
by date

Among the 112 studies in Carcinoma, Merkel Cell with a site in United States, this one is the 29th largest by planned enrollment of the 105 interventional ones that give a count, is one of 15 that started in 2019, is one of 36 in phase 1, reaches primary completion later than 10 of the 46 other live ones, and was the 58th registered.

Carcinoma, Merkel Cell

150 studies on the registry are indexed under Carcinoma, Merkel Cell; 39 are open to participants now.

Browse Carcinoma, Merkel Cell studies →

Open to participants now

26 of the 112 studies in Carcinoma, Merkel Cell with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Carcinoma, Merkel Cell studies recruiting now, 26 (79%) set no upper age limit and none (0%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Carcinoma, Merkel Cell with a site in United States, or all of them as a file.
02

Study summary

To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including Merkel Cell Carcinoma

Read the detailed description

Dose-escalation Phase: Approximately 48 patients are planned for the dose-escalation phase, with at least 6 patients treated at the RP2D.

Cohort Expansion Phase: Two additional cohorts are planned. Cohort E1: advanced ovarian cancer and Cohort E5 Merkel cell carcinoma. Each cohort will be treated at the RP2D.

In each cohort, FF-10850 will be administered intravenously (IV) until progression of disease, observation of unacceptable AEs, or, after discussion between the Investigator and the Medical Monitor, changes in the patient's condition that prevent further study participation. A sufficient number of cohorts will be enrolled to identify the RP2D.

There will be 3 initial dose levels in this study. FF-10850 will be diluted and infused over 60 minutes.

Approximately 96 patients are planned for the entire trial.

It is anticipated that approximately 4 centers will participate in the dose-escalation phase, with an expansion to approximately 10 centers in the cohort expansion phase. Accrual for the dose-escalation and expansion phases is expected to be approximately 3 years, with patients followed every 3 months from the last dose of study treatment to assess survival.

03

Conditions studied

  • Advanced Solid Tumors
  • Merkel Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all the following criteria to participate in the study:

  1. Males and females ≥ 18 years of age
  2. Dose-escalation phase: or cytologically confirmed and/or unresectable solid tumor, to standard therapy, or for which no standard therapy is available that is expected to improve survival by at least 3 months
  3. At least 3 weeks beyond the last chemotherapy (or 3 half-lives, whichever is shorter), radiotherapy, major surgery, or experimental treatment, and recovered from all acute toxicities (≤ Grade 1), prior to the first dose of FF-10850
  4. Adequate performance status: (ECOG) ≤ 1
  5. of ≥ 3 months
  6. Adequate hematologic parameters without ongoing transfusion support:

    • (Hb) ≥ 9 g/dL
    • (ANC) ≥ 1.0 × 109 cells/L
    • ≥ 100 × 109 cells/L
  7. Creatinine ≤ 1.5 × , or calculated ≥ 50 mL/minute by either the Cockcroft-Gault formula or as measured by a 24-hour urine collection
  8. Total ≤ 2 × ULN unless due to Gilbert's disease; patients with Gilbert's disease who have a total bilirubin > 6 mg/dL are to be excluded
  9. and AST ≤ 2.5 times ULN, or \< 5 × ULN for patients with liver metastases
  10. corrected for rate (QT interval corrected for rate using Fridericia's Correction Formula, QTcF) ≤ 470 msec for women and ≤ 450 msec for men on the obtained at Screening and confirmed pre-treatment on Cycle 1 Day 1.
  11. Patient must be willing to undergo a tumor , if the patient has a biopsy-accessible tumor

Exclusion criteria

Exclusion Criteria:

  1. Patients who have not received standard/approved therapies expected to improve survival by at least 3 months
  2. History of severe reactions to topotecan
  3. Serious cardiac condition within the last 6 months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina or heart disease defined by the (NYHA) Class III or Class IV or hereditary long syndrome
  4. Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, except for antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered by the Investigator to be essential for patient care
  5. Active central nervous system (CNS) malignant disease in patients with a history of CNS . Patients with previously treated stable are allowed if they have been stable off therapy for at least 4 weeks.
  6. Known positive for (HIV), virus surface antigen (HBsAg) or virus (HCV)
  7. Active infection requiring intravenous (IV) antibiotic usage within the last week prior to study treatment
  8. Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results
  9. Pregnant or breast-feeding
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Treatment at Dose Level 1

    FF-10850 Topotecan Liposome Injection, Dose Level 1 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle

    Drug: FF-10850 Topotecan Liposome Injection

  • Experimental
    Cohort 2: Treatment at Dose Level 2

    FF-10850 Topotecan Liposome Injection, Dose Level 2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle

    Drug: FF-10850 Topotecan Liposome Injection

  • Experimental
    Cohort 3: Treatment at Dose Level 3

    FF-10850 Topotecan Liposome Injection, Dose Level 3 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle

    Drug: FF-10850 Topotecan Liposome Injection

  • Experimental
    Cohort E1: Treatment at Recommended Phase 2 Dose (RP2D)

    For patients with advanced ovarian cancer: FF-10850 Topotecan Liposome Injection, RP2D administered intravenously (IV) on Days 1 and 15 of each 28-day cycle

    Drug: FF-10850 Topotecan Liposome Injection

  • Experimental
    Cohort E5: Treatment at Recommended Phase 2 Dose (RP2D)

    For patients with advanced Merkel cell carcinoma: FF-10850 Topotecan Liposome Injection, RP2D administered intravenously (IV) on Days 1 and 15 of each 28-day cycle

    Drug: FF-10850 Topotecan Liposome Injection

Interventions

  • DrugFF-10850 Topotecan Liposome Injection

    FF-10850 to be diluted and infused over 60 minutes.

    Also known as: FF-10850

06

What researchers measure

Primary outcomes

  1. Determine incidence of Treatment Emergent Adverse Events

    Safety and tolerability assessed by adverse events (AEs) and serious adverse events (SAEs)

    Time frame: 4 years

  2. Identify dose-limiting toxicities (DLT) of FF-10850

    DLT is defined as any adverse event at least possibly related to FF-10850, and meeting specified DLT criteria

    Time frame: 4 years

  3. Determine maximun tolerated dose (MTD) of FF-10850

    MTD is defined as the next lower dose of a cohort where patients experienced a DLT

    Time frame: 4 years

  4. Determine recommended Phase 2 dose (RP2D) FF-10850

    The highest dose level below the dose level eliciting DLT in ≥ 2 patients will be declared the MTD. The RP2D will be chosen based on the MTD or on PK and biological activity if an MTD has not been determined.

    Time frame: 4 years

Secondary outcomes

  1. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: Cmax

    Measurement of maximum plasma concentration

    Time frame: 4 years

  2. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: tmax

    Measurement of time to reach Cmax

    Time frame: 4 years

  3. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: t1/2

    Measurement of the elimination half-life

    Time frame: 4 years

  4. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: AUC

    Measurement of the area under the curve of plasma concentration versus time profile

    Time frame: 4 years

  5. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: MRT

    Measurement of the mean residence time adjusted for duration of infusion

    Time frame: 4 years

  6. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: CL

    Measurement of the total plasma clearance

    Time frame: 4 years

  7. Characterize the pharmacokinetics (PK) of FF-10850 in plasma: Vss

    Measurement of the steady-state volume of distribution for total topotecan

    Time frame: 4 years

  8. Determine objective response rate (ORR)

    classified for solid tumors via RECIST v.1.1

    Time frame: 4 years

  9. Determine the duration of response (DOR)

    Duration of Response is calculated from the date of first response to the date of progression or death.

    Time frame: 4 years

  10. Determine the time to progression (TTP)

    Time to progression is calculated from the date of first treatment to the date of first progression

    Time frame: 4 years

  11. Evaluate progression-free survival (PFS)

    Progression-free survival will be calculated from the date of first treatment to the date of progression or death

    Time frame: 4 years

  12. Evaluate overall survival (OS) (expansion cohorts only)

    Overall survival will be calculated from the date of first treatment to the date of death from any cause; patients who do not experience death will be censored at the last follow-up time.

    Time frame: 4 years

07

Study locations

7 sites
08

References and documents

Publications

  • Shimoyama S, Okada K, Kimura T, Morohashi Y, Nakayama S, Kemmochi S, Makita-Suzuki K, Matulonis UA, Mori M. FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment. Mol Cancer Ther. 2023 Dec 1;22(12):1454-1464. doi: 10.1158/1535-7163.MCT-23-0099. PubMed 37683276 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Dec 2026, 85 months after the start.

Of 25 phase 1 interventional studies under Carcinoma, Merkel Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 60. This study's planned 85 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2019
First posted
Aug 6, 2019
StartActual
Nov 14, 2019
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04047251
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Responsible party
Sponsor
First posted
Aug 6, 2019
Start date
Nov 14, 2019
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion